Topics covered: Winners and losers, Stocks picks, Shortage of cash, Regulatory outlook, R&D spending outlook, Potential acquisition targets, Negative financing environment, More generic drug usage, Molecular diagnostics growth area, Missed PDUFA dates, M&A Activity, IPO window, Investor interest, Follow-on biologics, FDA Approval Process, Expectation of more bankruptcies, Cost containment measures, Big Pharma interest in acquisitions, Activist shareholder action
